<DOC>
	<DOCNO>NCT02952820</DOCNO>
	<brief_summary>The key objective study determine , use sleep diary , whether lemborexant dos 5 milligram ( mg ) 10 mg superior placebo subjective sleep onset , subjective sleep efficiency , subjective sleep maintenance participant insomnia disorder .</brief_summary>
	<brief_title>Long-term Study Lemborexant Insomnia Disorder</brief_title>
	<detailed_description>This long-term ( approximately 1 year ) , multicenter , randomize , control , double-blind , parallel group study two dos lemborexant placebo approximately 900 male female participant insomnia disorder . Approximately 40 % participant age 65 year old . The study last maximum 59 week , include Screening Period , approximately 54-week Treatment Period ( study medication administer ) , 2-week Follow-up Period . All participant receive lemborexant least 6 month receive placebo point study . Participants know medication receive ( lemborexant placebo ) , know timing medication change .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Sleep Initiation Maintenance Disorders</mesh_term>
	<criteria>Male female , age 18 year old time inform consent Meets Diagnostic Statistical Manual Mental Disorders , Fifth Edition ( DSM 5 ) criterion Insomnia Disorder , follow : Complains dissatisfaction nighttime sleep form difficulty get sleep , difficulty stay asleep , and/or awaken earlier morning desire despite adequate opportunity sleep Frequency complaint ≥3 time per week Duration complaint ≥3 month Associated complaint daytime impairment History subjective sleep onset latency ( sSOL ) ≥30 minute least 3 night per week previous 4 week AND subjective wake sleep onset ( sWASO ) ≥60 minute least 3 night per week previous 4 week Reports regular time spend bed , either sleep try sleep , 7 9 hour Reports regular bedtime , define time participant attempt sleep , 21:00 24:00 regular waketime , define time participant get bed day , 05:00 09:00 Insomnia Severity Index ( ISI ) score ≥15 Confirmation current insomnia symptom determine response Sleep Diary Confirmation regular bedtime waketime , determine response Sleep Diary Confirmation sufficient duration time spend bed , determine response Sleep Diary Willing start behavioral treatment program insomnia study A current diagnosis sleeprelated breathe disorder , periodic limb movement disorder , restless legs syndrome , circadian rhythm sleep disorder , narcolepsy , exclusionary score screen instrument rule individual symptom certain sleep disorder insomnia Reports symptom potentially related narcolepsy clinical opinion investigator indicate need referral diagnostic evaluation presence narcolepsy On Munich Parasomnia Scale ( MUPS ) , ( ) history symptom Rapid Eye Movement ( REM ) Behavior Disorder , sleeprelated violent behavior , sleepdriving , sleepeating ; ( b ) symptoms another parasomnia investigator 's opinion make participant unsuitable study For participant underwent polysomnography ( PSG ) previous year : Age 18 64 year : Apnea Hypopnea Index ≥10 , Periodic Limb Movements Arousal Index ≥10 Age ≥65 year : Apnea Hypopnea Index &gt; 15 , Periodic Limb Movements Arousal Index &gt; 15 Beck Depression Inventory II ( BDI II ) score &gt; 19 Screening Beck Anxiety Inventory ( BAI ) score &gt; 15 Screening Habitually nap 3 time per week Females breastfeed pregnant Screening Study Baseline Females childbearing potential practicing acceptable pregnancy prevention method ( NOTE : All female consider childbearing potential unless postmenopausal sterilize surgically . ) Excessive caffeine use opinion investigator contribute participant 's insomnia , habitually consume caffeinecontaining beverage 18:00 unwilling forego caffeine 18:00 duration his/her participation study History drug alcohol dependency abuse within approximately previous 2 year Reports habitually consume 14 drink contain alcohol per week ( female ) 21 drink contain alcohol per week ( male ) , unwilling limit alcohol intake 2 drink per day forego alcohol within 3 hour bedtime duration his/her participation study Current evidence clinically significant disease ( e.g. , cardiac , respiratory , gastrointestinal , renal , neurological [ include participant lack capacity and/or whose cognitive decline indicate disorientation person/place/time and/or situation ] , psychiatric disease malignancy basal cell carcinoma ) chronic pain opinion investigator ( ) could affect participant 's safety interfere study assessment Comorbid nocturia result frequent need get bed use bathroom night Used prohibit prescription overthecounter concomitant medication within 1 week first dose study medication Used modality treatment insomnia , include cognitive behavioral therapy marijuana within 2 week Screening Failed treatment suvorexant ( Belsomra® ) ( efficacy and/or safety ) follow treatment appropriate dose adequate duration opinion investigator Transmeridian travel across 3 time zone 2 week Screening , Screening Baseline , plan travel across 3 time zone study Previously participate clinical trial lemborexant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>insomnia</keyword>
</DOC>